Flaim K E, Gessner G W, Crooke S T, Sarau H M, Weinstock J
Life Sci. 1985 Apr 15;36(15):1427-36. doi: 10.1016/0024-3205(85)90049-9.
Fenoldopam (SKF 82526), a dopamine agonist which exhibits D-1 receptor subtype selectivity, was evaluated as a radioligand for this receptor subtype. In saturation studies in rat striatal membrane preparations, [3H]-fenoldopam appeared to label a single binding site with a KD of 2.3 +/- 0.1 nM and a Bmax of 590 +/- 40 fmoles/mg protein. In competition binding experiments, binding was shown to be stereoselective, and rank ordering of affinities of dopaminergic and non-dopaminergic compounds closely correlated with potencies of these compounds in stimulating or inhibiting dopamine-sensitive adenylate cyclase (D-1) and in binding to D-1 sites labelled with the antagonist [3H]-cis-flupenthixol. The most potent competitors were the recently identified D-1 selective antagonists, SCH 23390 and SKF R-83566. [3H]-Fenoldopam was also used to assess agonist/D-1 receptor interactions. The results suggest that [3H]-fenoldopam is a useful and selective agonist radioligand for the D-1 receptor.
非诺多泮(SKF 82526)是一种具有D-1受体亚型选择性的多巴胺激动剂,被评估作为该受体亚型的放射性配体。在大鼠纹状体膜制剂的饱和研究中,[3H] - 非诺多泮似乎标记了一个单一的结合位点,其解离常数(KD)为2.3±0.1 nM,最大结合容量(Bmax)为590±40 fmol/mg蛋白质。在竞争结合实验中,结合表现出立体选择性,多巴胺能和非多巴胺能化合物的亲和力排序与这些化合物刺激或抑制多巴胺敏感腺苷酸环化酶(D-1)以及与拮抗剂[3H] - 顺式氟哌噻吨标记的D-1位点结合的效力密切相关。最有效的竞争者是最近鉴定出的D-1选择性拮抗剂SCH 23390和SKF R-83566。[3H] - 非诺多泮还用于评估激动剂/D-1受体相互作用。结果表明,[3H] - 非诺多泮是一种用于D-1受体的有用且选择性的激动剂放射性配体。